Acceleration of ventricular rate by fibrillation associated with the Wolff-Parkinson-White syndrome.
Amiodarone has proved to be a valuable drug in atrial fibrillation associated with the Wolff-Parkinson-White syndrome. When it was administered to a patient with this syndrome in atrial fibrillation, who had previously suffered an inferior myocardial infarction, the ventricular rate accelerated from 170 to 230 beats/minute.This unusual case emphasises the need for full electrophysiological assessment of patients with the Wolff-Parkinson-White syndrome for whom amiodarone treatment is being considered.
D000368:Aged; D000638:Amiodarone / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D001572:Benzofurans / Q000009:adverse effects*; D004562:Electrocardiography; D006801:Humans; D008297:Male; D013610:Tachycardia / Q000139:chemically induced*; D014927:Wolff-Parkinson-White Syndrome / Q000188:drug therapy*
D001572:Benzofurans; D000638:Amiodarone